Company intelligence / Profile preview

Breath Therapeutics

Ownership: Private
Development stage: Phase 3

Overview

The company is conducting multiple Phase 3 clinical trials (BOSTON-1, BOSTON-2, BOSTON-3, BOSTON-4) for L-CsA-i in the treatment of BOS in lung transplant and allogeneic hematopoietic stem cell transplant patients[1][5]

Therapeutic areas: Pulmonology
Modalities: Inhaled therapeuticsdrug-aerosol therapeuticsliposomal formulations
Industry: Biotech

Drug pipeline

1 asset

liposomal cyclosporine A

Phase 3

Indications: Bronchiolitis Obliterans Syndrome

Partnerships

PARI Pharma GmbH

Beyond the preview

Go deeper on Breath Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breath Therapeutics.

Explore the full profile